AN2 Therapeutics Pauses Trial: Efficacy Concerns Rise
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
- Latest
- Trending
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Discover the winners and losers in the stock market, including tech giants Microsoft and NVIDIA, as well as underperformers Intel ...
GSK and Elegen partner to develop new vaccines and medicines, harnessing Elegen's DNA manufacturing technology. Collaboration aims to expand genetic ...
Discover the promising future for investors in Eli Lilly and Company (NYSE: LLY), a leader in the biopharmaceutical industry, with ...
Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials
GSK's acquisition of Aiolos Bio expands respiratory treatment options, introducing AIO-001, a promising new treatment for asthma patients.
Calliditas Therapeutics reports strong Q4 growth and sets sights on expansion, with TARPEYO sales surging 170% in 2023. CEO optimistic ...
Licensing deals and ADCs drive biopharma deal flow in 2023, offering hope to an industry grappling with challenges. Big Pharma's ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.